The results of the single-mediator analysis are reported in Table 3 and show that the 12-month increase in adiponectin did not play a role as a mediator of the effect of baseline BMI on breast cancer risk (NIE: HR, 1.00; 95%CI, 0.98–1.02; Figure 2b). Here, ADIPOQ is linked to breast cancer.